 Heterocyclic Compounds, 2-Ring
"Heterocyclic Compounds, 2-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of heterocyclic compounds that include a two-ring fused structure. Both aromatic and non-aromatic ring structures are included in this category.
| Descriptor ID |
D006574
|
| MeSH Number(s) |
D03.633.100
|
| Concept/Terms |
Heterocyclic Compounds, 2-Ring- Heterocyclic Compounds, 2-Ring
- 2-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 2 Ring
- Two Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Two-Ring
- Fused Heterocyclic Compounds, Two Ring
|
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 2-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 2-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 2-Ring" by people in this website by year, and whether "Heterocyclic Compounds, 2-Ring" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 | | 2020 | 1 | 1 | 2 | | 2023 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Heterocyclic Compounds, 2-Ring" by people in Profiles.
-
Wright AC, Beaudoin FL, McQueen RB, Yeung K, Moradi A, Herron-Smith S, Gutierrez E, Lin GA, Pearson SD. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council. J Manag Care Spec Pharm. 2023 06; 29(6):692-698.
-
Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. Obstet Gynecol. 2023 04 01; 141(4):737-747.
-
Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020 12; 27(12):1350-1356.
-
Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, Skillern L, Ramael S. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020 04; 27(4):382-392.
-
Martin BS, Martinez-Botella G, Loya CM, Salituro FG, Robichaud AJ, Huntsman MM, Ackley MA, Doherty JJ, Corbin JG. Rescue of deficient amygdala tonic ?-aminobutyric acidergic currents in the Fmr-/y mouse model of fragile X syndrome by a novel ?-aminobutyric acid type A receptor-positive allosteric modulator. J Neurosci Res. 2016 Jun; 94(6):568-78.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|